Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Frontotemporal Dementia Market Sees Rise in Precision Medicine and Gene Therapy Approaches | DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

01 Jul, 2025, 21:31 GMT

Share this article

Share toX

Share this article

Share toX

The overall market for frontotemporal dementia is expected to grow with the anticipated launch of emerging therapies, including Latozinemab, PBFT02, TAK-594/DNL593, and others, increased awareness, and extensive research in the forecast period (2025–2034).

LAS VEGAS, July 1, 2025 /PRNewswire/ -- DelveInsight's Frontotemporal Dementia Market Insights report includes a comprehensive understanding of current treatment practices, frontotemporal dementia emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. 

Key Takeaways from the Frontotemporal Dementia Market Report

  • According to DelveInsight's analysis, the market size for frontotemporal dementia was found to be USD 60 million in the US in 2024.
  • According to DelveInsight's analysis, the total diagnosed prevalent cases of FTD in 7MM were found to be ~130K in 2024 and are estimated to rise with a significant CAGR throughout the forecast period (2025–2034). 
  • The highest proportion of FTD cases were observed in the bvFTD in the 7MM, while the fewest cases were found in language variant FTD (primary progressive aphasia).
  • Leading frontotemporal dementia companies developing emerging therapies, such as Alector, Passage Bio, Prevail Therapeutics, Denali Therapeutics, GSK, Vesper Bio, Takeda, and others, are developing new frontotemporal dementia treatment drugs that can be available in the frontotemporal dementia market in the coming years. 
  • The promising frontotemporal dementia therapies in the pipeline include Latozinemab, PBFT02, TAK-594/DNL593, PR006, VES001, and others.
  • Latozinemab, the most advanced therapy for FTD-GRN, with Orphan Drug Designation (ODD), Breakthrough Therapy (BTD), and Fast Track Designations for FTD, holds a strong regulatory momentum. 

Discover frontotemporal dementia new treatment @ New Treatments for Frontotemporal Dementia

Frontotemporal Dementia Market Dynamics

The frontotemporal dementia market dynamics are expected to change in the coming years. Emerging drugs are poised for market leadership due to the absence of an approved treatment for FTD, as rising case numbers drive urgent demand, renewed research interest fuels hope for improved diagnostics and expanded treatment options, and novel therapeutic approaches offer ample opportunities for breakthroughs.

As potential therapies are being investigated for the treatment of frontotemporal dementia, it is safe to predict that the treatment space will significantly impact the frontotemporal dementia market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the frontotemporal dementia market in the 7MM.

However, several factors may impede the growth of the frontotemporal dementia market. The exact pathology of the disorder remains unknown, and its heterogeneous nature makes clinical trials challenging, with few reaching completion; coupled with the high rate of misdiagnosis or delayed diagnosis, often due to symptom overlap with other disorders, these factors collectively weaken the market and pose significant hurdles for targeted treatment and the success of upcoming drugs.

Moreover, frontotemporal dementia treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the frontotemporal dementia market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the frontotemporal dementia market growth.

Frontotemporal Dementia Treatment Market 

The frontotemporal dementia treatment drug market is segmented by drug classes, including selective serotonin reuptake inhibitors (SSRIs) such as citalopram and fluoxetine, antipsychotics, cholinesterase inhibitors like donepezil, rivastigmine, and galantamine, NMDA receptor antagonists such as memantine, and benzodiazepine-based anti-anxiety medications.

SSRIs and related drugs are considered promising for FTD patients, as they have shown success in managing psychiatric symptoms that are similar to behavioral issues seen in FTD, particularly in those with the behavioral variant (bvFTD). Antidepressants and antipsychotics are frequently prescribed SSRIs for managing these symptoms.

However, research indicates that cholinesterase inhibitors are generally ineffective in treating FTD and progressive supranuclear palsy (PSP) and may even worsen behavioral or motor symptoms. Donepezil, rivastigmine, and galantamine remain the most commonly administered cholinesterase inhibitors in FTD and similar conditions. Memantine, an NMDA receptor antagonist approved for Alzheimer's disease, has been explored for its potential neuroprotective effects by targeting excitotoxicity linked to NMDA receptor overactivity.

Complementary therapies also play a vital role in FTD management. Physical therapy focusing on gait and balance can help reduce fall risk and improve survival. Speech therapy, particularly with specialists in neurodegenerative aphasias, benefits individuals with primary progressive aphasia. Additionally, occupational therapy assessments for home safety can enhance daily functioning for those with motor coordination difficulties or apraxia.

Growing research interest in FTD is paving the way for future breakthroughs and the development of innovative treatments targeting new molecular pathways.

To know more about FDA-approved drugs for frontotemporal dementia, visit @ Frontotemporal Dementia Treatment Drug Market

Frontotemporal Dementia Pipeline Therapies and Key Companies

Companies across the globe are diligently working toward the development of novel treatment therapies with considerable amount of success over the years. To date, there are a few emerging market players, Alector/GSK (latozinemab), Passage Bio (PBFT02), Prevail Therapeutics (PR006), Denali Therapeutics/Takeda (TAK-594/DNL593), Vesper Bio (VES001), and others that are developing therapies for the treatment of FTD. 

Alector's lead candidate, Latozinemab, is a monoclonal antibody aimed at regulating progranulin, an immune system modulator in the brain that has genetic associations with several neurodegenerative conditions. It is currently undergoing Phase III clinical evaluation for the treatment of FTD-GRN. Developed in partnership with GSK, Latozinemab has received Orphan Drug Designation (ODD) for FTD, along with Breakthrough Therapy Designation (BTD) and Fast Track status from the U.S. FDA for FTD-GRN. The ongoing global INFRONT-3 Phase III trial is enrolling both symptomatic and at-risk individuals with FTD-GRN.

Passage Bio is developing PBFT02, a gene therapy that employs an AAV1 vector to deliver a modified GRN gene to patient cells. The therapy is under investigation in Phase I/II trials for FTD with GRN mutations, supported by an active IND from the FDA and regulatory approvals in multiple countries. Following encouraging regulatory feedback on its clinical development path for FTD-C9orf72, Passage Bio plans to begin dosing in the upliFT-D trial in the first half of 2025.

Denali Therapeutics, in collaboration with Takeda, is advancing TAK-594 (also known as DNL593), an IV-administered progranulin replacement therapy enabled by its proprietary Protein Transport Vehicle (PTV) platform. Progranulin supports lysosomal health and exhibits neuroprotective and anti-inflammatory properties. DNL593 leverages "brain shuttle" technology to deliver progranulin across the blood–brain barrier. Data from an ongoing Phase I/II trial in healthy volunteers showed dose-dependent increases in CSF progranulin levels, indicating effective brain delivery. Dosing in FTD-GRN patients is currently in progress.

Prevail Therapeutics is working on PR006, a one-time gene therapy targeting FTD-GRN. This therapy uses an AAV9 vector to deliver a functional GRN gene to boost progranulin levels in patients' brains. PR006 has been granted Orphan Drug Designation in both the U.S. and Europe, as well as Fast Track designation from the U.S. FDA for FTD-GRN. It is currently being evaluated in the PROCLAIM Phase I/II clinical trial in FTD-GRN patients.

The anticipated launch of these emerging therapies are poised to transform the frontotemporal dementia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the frontotemporal dementia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about frontotemporal dementia drugs in development @ Frontotemporal Dementia Clinical Trials 

Recent Developments in the Frontotemporal Dementia Market

  • In May 2025, Vesper Bio announced that it had reached an important enrolment milestone in the Phase Ib/IIa of its ongoing SORT-IN-2 study of VES001 for GRN-FTD.
  • In May 2025, Passage Bio presented the process development data of a high productivity, suspension-based manufacturing process for PBFT02 at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting 2025.

Frontotemporal Dementia Overview

Frontotemporal dementia (FTD) is a neurocognitive disorder marked by progressive impairment in executive function, behavior, and language. Its clinical presentation is highly variable, encompassing behavioral shifts, emotional disturbances, communication challenges, and sometimes motor deficits. A significant risk factor is family history, with 15–40% of cases associated with genetic mutations, though the precise underlying cause often remains unidentified. 

Diagnosis is difficult due to the broad and overlapping nature of symptoms with other neurological or psychiatric conditions, the absence of definitive biomarkers, and the reliance on thorough clinical evaluation. Misdiagnosis is frequent, as FTD can closely resemble psychiatric illnesses or other forms of dementia, making accurate detection challenging.

Frontotemporal Dementia Epidemiology Segmentation

The frontotemporal dementia epidemiology section provides insights into the historical and current frontotemporal dementia patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The frontotemporal dementia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:

  • Frontotemporal Dementia Diagnosed Prevalent Cases
  • Type-specific Frontotemporal Dementia Diagnosed Prevalent Cases
  • Gene-specific Frontotemporal Dementia Diagnosed Prevalent Cases

Frontotemporal Dementia Market Report Metrics

Details

Study Period

2020–2034

Coverage

7MM [The United States, the EU4 (Germany, France, Italy, and Spain) and The United Kingdom, and Japan].

Frontotemporal Dementia Market Size in 2024 (US)

USD 60 Million

Key Frontotemporal Dementia Companies

Alector, Passage Bio, Prevail Therapeutics, Denali Therapeutics, GSK, Vesper Bio, Takeda, and others

Key Frontotemporal Dementia Therapies

Latozinemab, PBFT02, TAK-594/DNL593, PR006, VES001, and others

Scope of the Frontotemporal Dementia Market Report

  • Therapeutic Assessment: Frontotemporal Dementia current marketed and emerging therapies
  • Frontotemporal Dementia Market Dynamics: Key Market Forecast Assumptions of Emerging Frontotemporal Dementia Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Frontotemporal Dementia Market Access and Reimbursement

Download the report to understand which factors are driving frontotemporal dementia market trends @ Frontotemporal Dementia Market Forecast

Table of Contents

1.

Frontotemporal Dementia Market Key Insights

2.

Frontotemporal Dementia Market Report Introduction

3.

Frontotemporal Dementia Market Overview at a Glance

4.

Frontotemporal Dementia Market Executive Summary

5.

Disease Background and Overview

6.

Frontotemporal Dementia Treatment and Management

7.

Frontotemporal Dementia Epidemiology and Patient Population

8.

Patient Journey

9.

Frontotemporal Dementia Marketed Drugs

10.

Frontotemporal Dementia Emerging Drugs

11.

Seven Major Frontotemporal Dementia Market Analysis

12.

Frontotemporal Dementia Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Unmet Needs

16.

SWOT Analysis

17.

Appendix

18.

DelveInsight Capabilities

19.

Disclaimer

20.

About DelveInsight

Related Reports

Frontotemporal Dementia Pipeline

Frontotemporal Dementia Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key FTD companies, including Alector, GSK, Eli Lilly and Company, Transposon Therapeutics, Passage Bio, AviadoBio, Vesper Bio, Neurimmune Therapeutics, Asceneuron SA, among others.

Frontotemporal Dementia Epidemiology Forecast

Frontotemporal Dementia Epidemiology Forecast – 2034 report delivers an in-depth understanding of FTD epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Alzheimer's Disease Market

Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies including AB Science, Alzheon Inc., AriBio Co., Ltd., AgeneBio, Inc., Anavex Life Sciences Corp., Annovis Bio, Inc., Cerecin, BioVie, Cassava Sciences, Novo Nordisk, Eli Lilly, Neurim Pharmaceuticals, Suven Life Sciences, Bristol-Myers Squibb, Karuna Therapeutics, T3D Therapeutics, Inc., Lexeo Therapeutics, Axsome Therapeutics, Inc., Araclon Biotech S.L., Eisai Co., Ltd., TauRx Therapeutics, TrueBinding, Inc., AC Immune SA, Johnson & Johnson, Longeveron Inc., Vaccinex Inc., IGC Pharma LLC, among others.

Dementia Market

Dementia Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dementia companies including Eisai Co., Ltd., Eli Lilly and Company, Novartis AG, DAIICHI SANKYO COMPANY, LIMITED, AbbVie Inc., Lundbeck, Biogen, Cipla, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur  
info@delveinsight.com
+14699457679
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg 

Modal title

Also from this source

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion | DelveInsight

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion | DelveInsight

DelveInsight's GPCR-Targeting Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Post-Traumatic Stress Disorder Market Set to Expand Significantly During the Study Period (2020-2034) with Pipeline Innovation and Unmet Needs | DelveInsight

Post-Traumatic Stress Disorder Market Set to Expand Significantly During the Study Period (2020-2034) with Pipeline Innovation and Unmet Needs | DelveInsight

DelveInsight's Post-Traumatic Stress Disorder Market Insights report includes a comprehensive understanding of current treatment practices,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.